Repositorio
Institucional

Janjigian, Yelena Y.

Shitara, Kohei

Moehler, Markus

Garrido, Marcelo

Salman, Pamela

Wyrwicz, Lucjan

Yamaguchi, Kensei

Skoczylas, Tomasz

Bragagnoli, Arinilda Campos

Liu, Tianshu

Schenker, Michael

Yanez, Patricio

Tehfe, Mustapha

Kowalyszyn, Ruben

Karamouzis, Michalis V.

Bruges, Ricardo

Zander, Thomas

Pazo-Cid, Roberto

Hitre, Erika

Feeney, Kynan

Cleary, James M.

Poulart, Valerie

Cullen, Dana

Lei, Ming

Xiao, Hong

Kondo, Kaoru

Li, Mingshun

Ajani, Jaffer A.

A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus

FUTURE MEDICINE LTD

FUTURE ONCOLOGY

en

What is this summary about? This is a summary of the 1-year results of a clinical research study known as CheckMate 649 published in The Lancet in June 2021. The 2-year results on the participants' health and overall quality of life from the same study are in a second publication in Nature in March 2022. Until recently, chemotherapy was the only first treatment option for people with advanced or metastatic gastroesophageal adenocarcinoma who had not been treated before. Patients receiving chemotherapy lived on average for less than 1 year. Nivolumab is an immunotherapy that works by activating a person's immune system to fight back against cancer cells. The goal of CheckMate 649 was to find out if the combination of nivolumab and chemotherapy would help patients with advanced or metastatic gastroesophageal adenocarcinoma live longer and without their cancer getting worse. What were the results? Results from the final analysis are reported here. Of 1581 people who took part in the study, 789 received nivolumab and chemotherapy and 792 received chemotherapy. Researchers found that, on average, participants who received nivolumab and chemotherapy lived longer overall than those who received chemotherapy alone. The length of time participants lived without their cancer getting worse was also longer on average with nivolumab and chemotherapy than chemotherapy treatment alone. However, more participants in the nivolumab and chemotherapy group had side effects than those in the chemotherapy group. The three most common side effects in both types of treatment were nausea (urge to vomit), diarrhea and peripheral neuropathy. Participants who received nivolumab and chemotherapy had a lower risk of their cancer symptoms worsening and reported that they were 'less bothered' from side effects of treatment than those receiving chemotherapy alone. What do the results mean? The nivolumab and chemotherapy combination is considered a new standard treatment option and is approved in several countries as a treatment for adults who have not been treated before for their advanced or metastatic gastroesophageal cancer based on results from CheckMate 649. Clinical Trial Registration: NCT02872116 (ClinicalTrials.gov)

2023

artículo original

10.2217/fon-2022-1149

PDF

adenocarcinoma

chemotherapy

esophageal cancer

gastric cancer

gastroesophageal junction cancer

immune checkpoint inhibitor

immunotherapy

lay summary

nivolumab

plain language summary

Oncología

adenocarcinoma

quimioterapia

cáncer de esófago

cáncer gástrico

cáncer de la unión gastroesofágica

inhibidor de puntos de control inmunológico

inmunoterapia

resumen laico

nivolumab

resumen en lenguaje sencillo

versión publicada

hibrida

verde

acceso abierto

acceso abierto

WOS:000961631900001

739.0

752

artículo original

CC BY NC-ND

CC BY NC-ND

1479-6694

Oncología